Home
About Us
Our Technology
Our Pipeline
Patients
Investors & Media
Career
Contact Us
EN—CN

Proprietary and Revolutionary Technology Platforms
Propel cancer immunotherapy advancements

Proprietary and Revolutionary
Technology Platforms
Propel cancer immunotherapy
advancements

OriAb Antibody Discovery Platform

Our OriAb platform represents one of the largest and most diversified antibody libraries to screen and optimize antibodies for CAR-T programs. OriAb platform comprises 1011 full human naïve phage display antibodies and 1011 synthetic nanobodies. We have mastered know-hows to effectively identify binders with tuned affinities and avidities to target tumor associated antigens and make different characteristics of TAAs to work for our CAR-Ts.

OriAb Antibody Discovery Platform

We have constructed a large scale of 1011 full human naïve phage display library and a 1011 synthetic nanobody library through innovative methods. The synthetic nanobody library, NanoOri_2.0 series in particular, contains both "upright" and "roll" conformations with different length of CDR for screening candidate antibodies against different types of antigens, with sub-libraries especially desiged for CAR-T with low CAR-tonic signaling.

These libraries provide an extraordinary advantage in our mission to discover specific antibodies against various tumor targets. We can efficiently identify a broad spectrum of tumor-specific targets-binding epitopes on a large scale, offering comprehensive candidate sequences. This opens up opportunities to uncover antibodies with superior binding properties, even for challenging targets like GPRC5D. The highly specific antibodies we unearth are proficient at selectively targeting tumor cells while mitigating the risks of CAR-T product self-activation and rapid exhaustion.

In addition, we have designed a unique antibody engineering process, including affinity maturation, humanization, and antibody format modification. This process ensures that we optimize antibodies with the most appropriate affinities for different targets, making them invaluable assets in CAR-T therapies.

OriCAR
CAR-T Platform

Our design incorporates a series of OriCAR signal components, enhancing the cytotoxicity of CAR-T cells against both hematologic and solid tumors through multiple mechanisms. This effectively improves the killing efficacy of CAR-T cells against tumors, reducing the risk of relapse and enhancing tolerance.

OriCAR CAR-T Platform

Our OriCAR platform generates CAR constructs that deliver a combination of enhanced infiltration, high memory T cells, anti-exhaustion and anti-tumor activities. Such features are successfully converted into clinical efficacy, safety and durability. OriCAR-017 Lancet →

On top of these, our state-of-art CMC capabilities put the design to work.

01High memory T cells ratio

02Enhanced infiltration

03Resistant to exhaustion in TME

04Superior anti-tumor activities

Strong In-house CMC Capability

  • Quality Management System

    ·QMS in compliance with NMPA requirements

    ·Onsite QC testing, QA reviewing and QP approval for batch release

  • GMP Manufacturing

    ·1200m2 Cleanrooms, 4 class B cell production suites

    ·Automated systems for real-time review of process data and release of product

  • Analytical and Process Development

    ·Experienced development team with well known leaders in the industry

    ·Knowledgeable in cell function-based bioassay development

    ·In-depth know-how for cell therapy product development, characterization and validation

  • 自主病毒开发和生产

    ·4质粒包装系统

    ·LVV产能较CDMO提升4-5倍

    ·已验证可装载复杂CAR结构，目的基因最大可达4.4kb

Closed System For CAR-T manufacture

Leukapheresis

T cell Enrichment

T cell Activation

Transduction

Cell Expansion

Harvest

Formulation and Fill

Cryopreservation

QC and Release

Infusion

  • 4highly secure
    plasmid system

    for lentivirus packaging

  • 50 - 80%

    Transduction rates

  • 7-9Days

    Manufacturing time

  • 8-10Days

    QC and QP release times

Explore and Discover
Learn more about results and applications

More

We are globally seeking for collaboration partner for our leading CAR-T program OriCAR-017 (GPRC5D targeting, excellent IIT data obtained and IND approved P1 ongoing in China), Oricell T-cell Engager Platform, Tumor immune microenvironment (TME) Modulator and Innovative preclinical antibody programs.

  • GPRC5D CAR T Program

    OriCAR-017

    ·GPRC5D is a well validated target for Multiple Myeloma as JNJ had launched FiC CD3*GPRC5D BsAb in Aug, 2023.

    ·Oricell OriCAR-017 demonstrates best-in-class potential among therapies targeting GPRC5D (100% ORR, 100% MRD negative and 80% sCR from IIT study), for heavily treated R/R Multiple Myeloma patients, including those who relapsed from prior BCMA CAR T-cell therapy.

    ·OriCAR-017 is IND approved in China and FDA IND application is planned in Dec 2023, expected to be the 2nd GPRC5D targeting CAR-T to enter into Ph1 in US.

    ·Oricell seeks to team up with strong player in malignant hematology and cell therapy to accelerate the drug development of OriCAR-017 out of China.

  • 4-1BB based T-cell Engager (TCE) Platform

    ·Leading product PD-L1*4-1BB BsAb demonstrates excellent safety profile and broad therapeutic potential, multi-region phase 1 study ongoing (US, China and Australia), partnered with Antengene

    ·Oricell aims to work with partner to develop more potent and safe TAA targeting therapy (TAA*4-1BB TCE). Multiple TAA targeting antibodies with high affinity and specificity readily available

  • Tumor immune microenvironment (TME) Modulator

    ·The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity within the tumor microenvironment. Consequently, multiple clinical strategies are being explored to target this pathway for the treatment of cancer.

    ·Oricell’s blocking antibodies targeting the key proteins in ATP–adenosine pathway with high affinity and specificity, showed superior anti-tumor efficacy than clinical stage benchmark antibody, both in vitro and in vivo studies.

    ·Open for collaboration either as final product or as building module for novel molecule (BsAb, MsAb etc.)

  • Innovative preclinical antibody programs

    ·Multiple TAA targeting antibody with fine-tuned affinity and high specificity

    ·Multiple Immune checkpoint inhibitor antibody with high affinity and high specificity

    ·Open for collaboration either as final product or as building module for novel molecule (BsAb, MsAb, ADC etc.)

Collaboration: bd@oricell.com

Thinkart